Abstract
Plasma samples from patients undergoing treatment in malaria endemic countries often contain anti-malaria drugs, that may overstate effects of specific antibodies in growth inhibition assays (GIA). We describe a modified assay that uses drug resistant P. falciparum parasites (W2) that circumvents the requirement for dialyzing samples that may likely contain drugs such as chloroquine and sulfadoxine/pyrimethamine (SP).
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Antibodies, Protozoan / blood*
-
Antibodies, Protozoan / immunology
-
Antimalarials / blood
-
Antimalarials / pharmacology
-
Chloroquine / blood
-
Chloroquine / pharmacology
-
Dialysis
-
Dose-Response Relationship, Immunologic
-
Drug Resistance
-
Humans
-
L-Lactate Dehydrogenase / analysis
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / growth & development*
-
Plasmodium falciparum / immunology
-
Pyrimethamine / pharmacology
Substances
-
Antibodies, Protozoan
-
Antimalarials
-
Chloroquine
-
L-Lactate Dehydrogenase
-
Pyrimethamine